HighTower Advisors
DMAC icon

HighTower Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

HighTower Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Buy
17,075
+6,076
+55% +$37.3K ﹤0.01% 3634
2026
Q1 		$74.5K Buy
+10,999
New +$87.2K ﹤0.01% 3668

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

HighTower Advisors's DMAC Position: Q2 2026 in Review

HighTower Advisors increased its DiaMedica Therapeutics (DMAC) stake by 55% in Q2 2026, buying an estimated $37.3K and bringing the position to 17,075 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

HighTower Advisors first reported a position in DMAC in Q1 2026 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • HighTower Advisors held 17,075 shares of DiaMedica Therapeutics worth $120K as of Q2 2026.
  • HighTower Advisors bought 6,076 DiaMedica Therapeutics shares in Q2 2026, an estimated $37.3K.
  • DiaMedica Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3634 holding.
  • HighTower Advisors first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.